NCT05015374Completed
Effect of Astaxanthin on the Patients With Alzheimer Disease
Source: ClinicalTrials.gov · Last updated 27 Sept 2024
Brief summary (registry, in English)
This study adapts a randomized, double-blind, placebo-controlled trial, to exam the possible benefit of Astaxanthin on Alzheimer disease. The enrolled Alzheimer patients will take Astaxanthin or placebo for 1 year. We will follow up Mini-Mental State Examination, Cognitive Ability Screening Instrument, Clinical Dementia Rating, and Neuropsychiatric Inventory at the end of the study.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 12 Aug 2021
- Start date
- 14 Nov 2018
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT05015374
What you commit to
- Study type: Interventional
- Participants enrolled: 46
- From 14 Nov 2018 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- New cerebrovascular disease happens during 3-year follow up
- Mixed type dementia
- Major psychiatric disease (such as depression, bipolar disorder, schizophrenia) or substance abuser (such as alcohol, illegal drug, hypnotics)
- Heart failure, end stage renal disease, liver cirrhosis, or other major organ failure
- Severe hearing impairment results in incomplete survey of neuropsychatric evaluation
Other
- Not using or poor medical adherence to donepezil、rivastigmine or galantamine
- Combined using memantine or other cerebral perfusion enhancing agent, such as Piracetam, Dihydroergotoxine, Nicergoline etc.
- No informed consent or no regular follow up
Who the study is looking for
- 60 ≦ age ≦ 90
- Clinical Dementia Rating Scale = 0.5 or 1
- Under treatment with donepezil、rivastigmine or galantamine with good medical adherence
- Get a signed informed consent from the patient or his/her family
Age in the registry: 60 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kaohsiung Medical University Chung-Ho Memorial Hospital Coordinator of this site? Confirm its status | Kaohsiung City | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.